首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal ThrombopoietinReceptor Antibody

  • 中文名： Thrombopoietin Receptor抗体
  • 别    名： MPL; TPOR; Thrombopoietin receptor; TPO-R; Myeloproliferative leukemia protein; Proto-oncogene c-Mpl; CD110
货号: IPDX23037
Price： ￥1180
数量：
大包装询价

验证与应用

应用及物种
WB 1/500-1/1000 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesMPL; TPOR; Thrombopoietin receptor; TPO-R; Myeloproliferative leukemia protein; Proto-oncogene c-Mpl; CD110
Entrez GeneID4352
WB Predicted band sizeCalculated MW: 71 kDa; Observed MW: 82 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman,Mouse,Rat
ImmunogenA synthesized peptide derived from human TPOR
FormulationPurified antibody in PBS with 0.05% sodium azide.

+ +

参考文献

以下是3篇关于TPO受体抗体的文献摘要信息(注：TPO受体激动剂多指小分子或肽类药物，严格抗体类较少，以下包含相关药物研究)：

1. **文献名称**: *Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial*

**作者**: Townsley DM et al.

**摘要**: 该II期临床试验评估了TPO受体激动剂romiplostim(Fc-肽融合蛋白)在免疫抑制治疗无效的再生障碍性贫血患者中的疗效。结果显示，40%患者出现血液学缓解，且耐受性良好，支持其作为难治性患者的潜在治疗选择。

2. **文献名称**: *Eltrombopag for the treatment of chronic immune thrombocytopenia*

**作者**: Bussel JB et al.

**摘要**: 研究证实口服小分子TPO受体激动剂eltrombopag可显著提升慢性免疫性血小板减少症(ITP)患者血小板计数，减少出血风险。长期随访显示持续应答且安全性可控，但需监测肝酶异常。

3. **文献名称**: *Thrombopoietin receptor agonists: a critical review*

**作者**: Kuter DJ.

**摘要**: 综述系统分析了TPO受体激动剂(包括抗体类romiplostim)的作用机制及临床应用，强调其在ITP、化疗导致血小板减少等疾病中的疗效，同时讨论血栓形成风险和个体化用药策略。

背景信息

Thrombopoietin receptor (TPO-R), also known as MPL, is a cytokine receptor critical for regulating megakaryocyte development and platelet production. It binds thrombopoietin (TPO), initiating signaling cascades (e.g., JAK-STAT, MAPK) that drive megakaryocyte proliferation and differentiation. TPO-R antibodies are therapeutic or diagnostic tools targeting this receptor. Agonistic antibodies (e.g., romiplostim, eltrombopag) mimic TPO to stimulate platelet production, widely used in immune thrombocytopenia (ITP) and chemotherapy-induced thrombocytopenia. These agents bind TPO-R extracellular domains, activating downstream pathways to boost platelet counts, with FDA approval for chronic ITP. Conversely, antagonistic TPO-R antibodies inhibit receptor activity, explored in myeloproliferative disorders like myelofibrosis, where aberrant TPO signaling contributes to disease progression. Research also investigates autoantibodies against TPO-R in autoimmune conditions, which may impair platelet production. Challenges include balancing efficacy with thrombotic risks in agonist therapies and minimizing off-target effects. Emerging antibody engineering aims to enhance receptor specificity and pharmacokinetics. TPO-R antibodies thus represent a dual-edged therapeutic avenue, offering targeted strategies for hematologic disorders while underscoring the need for precise modulation of thrombopoiesis pathways. Ongoing studies focus on optimizing clinical applications and understanding receptor-antibody interactions at molecular levels.

客户数据及评论

折叠内容

大包装询价

×